AVITA Medical (ASX:AVH): RECELL Sales, Cash Use and the Next Earnings Update

Aditi Sarkar

02 November 2026 06:13 PM AEDT

AVITA Medical (ASX:AVH): RECELL Sales, Cash Use and the Next Earnings Update

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

AVITA Medical, Inc. (ASX:AVH) closed at AUD 4.43 on 2 November 2026.
For the quarter ended 30 June 2026, AVITA Medical (ASX:AVH) reported net Revenue of USD 21.7 million, an 18% YoY increase and a 13% sequential rise.
AVITA Medical (ASX:AVH) reported a second-quarter gross Margin of 81.9%, compared with 81.2% a year earlier.
Cash flow, execution and business-specific risks remain key monitoring points.

AVITA Medical, Inc. (ASX:AVH) develops and commercialises products used in acute wound care, including its RECELL skin-cell therapy platform and the Cohealyx and PermeaDerm wound products. Shares closed at AUD 4.43 on 2 November 2026. Its August 2026 second-quarter results described increased product sales, lower cash use and revised annual revenue guidance, while third-quarter Earnings were scheduled for release in November.

How the Wound-Care Portfolio Generates Revenue

AVITA Medical (ASX:AVH) sells wound-treatment technologies to healthcare providers, with RECELL contributing most of its disclosed quarterly revenue. RECELL enables clinicians to prepare a suspension of a patient’s skin cells for treatment of indicated wounds. The company also markets Cohealyx, a collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. These products address different stages of wound management and have distinct commercial economics. RECELL revenue is therefore an important measure of established demand, while uptake of the other products illustrates portfolio diversification.

Second-Quarter Results and 2026 Commercial Developments

For the quarter ended 30 June 2026, AVITA Medical (ASX:AVH) reported net revenue of USD 21.7 million, an 18% YoY increase and a 13% sequential rise. RECELL contributed USD 18.5 million, Cohealyx USD 1.7 million and PermeaDerm USD 0.6 million, with international sales of USD 0.9 million. These amounts describe different commercial lines rather than a measure of clinical outcomes. The company also reported positive PermeaDerm study results in August 2026, outlining clinical comparability and its own economic analysis. Further adoption depends on hospital purchasing decisions and product use.

Operating Costs, Liquidity and Guidance

AVITA Medical (ASX:AVH) reported a second-quarter gross margin of 81.9%, compared with 81.2% a year earlier. Operating expenses were USD 24.6 million, down 6% YoY. Net cash use of approximately USD 3.2 million compared with USD 9.9 million in the March quarter. Cash, equivalents and marketable securities totalled approximately USD 11.1 million at 30 June 2026. The company raised its 2026 net revenue guidance to USD 86–89 million and stated that it expected fourth-quarter cash-flow breakeven. Both figures were management guidance rather than completed results.

Risks and What to Watch

A key issue for AVITA Medical (ASX:AVH) is whether sales collections and operating costs allow the company to meet its cash-flow objective without additional funding. Product reimbursement, procurement procedures, clinical adoption and competition can affect commercial outcomes. Changes in gross margin may also occur as revenue from products with different Economics grows. The company announced that its third-quarter results would be released on 5 November 2026, offering a further test of revenue trends and liquidity.

The difference between revenue growth and cash generation is particularly relevant for a medical-device business. Hospital Demand can rise while collections, product Manufacturing and commercial expenses occur on different schedules. Quarter-to-quarter liquidity therefore provides information not captured by sales alone.

The August announcement distinguished guidance from historical performance. Reported revenue and operating expenses refer to the June quarter; the full-year range and expected breakeven date require subsequent verification. The next release can establish how much of that anticipated improvement occurred.

Key Insights

AVITA Medical (ASX:AVH) reported higher second-quarter revenue and lower sequential cash use, alongside a modest quarter-end liquidity balance. Its revised guidance and planned third-quarter reporting create measurable follow-up points. Cash conversion, RECELL demand, adoption of companion products and reimbursement settings remain relevant to assessing the 2026 operating trajectory.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.